Citation Impact
Citing Papers
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Mismatch repair and treatment resistance in ovarian cancer
2006
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m 6 A-demethylation of NANOG mRNA
2016 StandoutNobel
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
2005
A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
1999
A Population-Based Study of Patterns of Care for Ovarian Cancer: Who Is Seen by a Gynecologic Oncologist and Who Is Not?
2002
Testicular Germ-Cell Cancer
1997 Standout
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Tubulin interacting agents: Novel taxanes and epothilones
2003
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
2010 Standout
DNA methylation patterns and epigenetic memory
2002 Standout
Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria
1996
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Ovarian cancer
2014 Standout
Timing of debulking surgery in advanced ovarian cancer
2008
Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
2000
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts
1993
PET and [18F]-FDG in oncology: A clinical update
1996
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Renal-Cell Carcinoma
1996 Standout
Anticancer therapy with novel tubulin-interacting drugs
2001
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Traumatic brain injury
2000 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
2006
Individual patient data analysis to assess modifications to the RECIST criteria
2008
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
2000
Management of Hepatocellular Carcinoma *
2005 Standout
An update on satraplatin: the first orally available platinum anticancer drug
2000
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Diagnostic open laparoscopy in the management of advanced ovarian cancer
2005
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
2004
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
1995 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue
1998
Cardiotoxicity of Chemotherapeutic Agents
2000
Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study
1993
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Carboplatin: current status and future prospects
1988
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals
2003 Standout
DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action
2000
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998
Cytoreductive surgery for advanced stages of ovarian cancer
2000
Microtubules as a target for anticancer drugs
2004 Standout
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
2006
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
1997
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients
1998
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
2014
Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types
2007
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
New platinum antitumor complexes
1993
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma
2005
The fundamental role of epigenetic events in cancer
2002 Standout
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Satraplatin: an orally available platinum analog for the treatment of cancer
2006
Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
2006
Cancer of the Ovary
2004 Standout
Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate
2002
Gemcitabine Plus Paclitaxel in Breast Cancer
2005
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
2007
The University of Toronto Head Injury Treatment Study: A Prospective, Randomized Comparison of Pentobarbital and Mannitol
1984
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
1986
Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked
1997 StandoutScience
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
2014 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide
1987 Standout
Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.
1994
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Extending Survival with Chemotherapy in Metastatic Breast Cancer
2005
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells
2005
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Etoposide (VP-16–213)
1985
Advances in Copper Complexes as Anticancer Agents
2013 Standout
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)
1983
Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action
2007
Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial
2003
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
2001
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Works of J. Renard being referenced
Phase II study of 5-Aza-2′-deoxycytidine in advanced ovarian carcinoma
1990
The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
1995
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
1998
Phase II trial with Flavone Acetic Acid (NSC.347512, LM975) in patients with non-small cell lung cancer
1992
Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: A study of the Early Clinical Trials Group of the EORTC
1990
Phase II study of iproplatin in advanced ovarian carcinoma.
1988
Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG)
1988
The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
1987
Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer
1993
Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy
1988
Phase II study of amsacrine in solid tumors: a report of the EORTC early clinical trial-group
1983
Phase II study of oral VP-16-213 in hepatocellular carcinoma
1981
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
2002
Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck
1987
The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
1995
The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study
1996
Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial
2001
Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies
1999
Quality of Institutional Participation in Multicenter Clinical Trials
1981
A phase II study of oral VP-16-213 in non-seminomatous testicular cancer
1981
Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
1990